» Articles » PMID: 1974503

The Use of Carvedilol in Elderly Hypertensive Patients

Overview
Specialty Pharmacology
Date 1990 Jan 1
PMID 1974503
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Carvedilol, a beta-blocking drug with vasodilator activity, has been used in 4 studies in 107 elderly patients with essential hypertension and has reduced blood pressure effectively. In the first study the pharmacokinetics and clinical response were compared between 21 patients greater than 65 years of age and 8 patients aged 35-50 years). The peak blood levels, time to maximal concentration, area under the curve, half-life and trough level of the drug with chronic administration did not differ. The clinical responses to the drug were similar, with a greater fall in systolic blood pressure in the older group. However the initial systolic blood pressure in the older group was higher. Carvedilol was compared with metoprolol, pindolol and nitrendipine in elderly patients. The responses to carvedilol were at least equal to those obtained with the other drugs. Control was achieved in the three studies with once-daily therapy. There was no significant postural hypotensive effect. A feature of all studies was the large number of patients who responded to carvedilol. The side-effect profile of the drug was acceptable; headache and dizziness were more common than with placebo or the comparison drugs and were frequently associated. There were no adverse biochemical effects and the lipid profile was not altered. Carvedilol is an effective antihypertensive drug that lowers blood pressure equally well in the young and the old.

Citing Articles

Carvedilol: a review of its use in chronic heart failure.

Keating G, Jarvis B Drugs. 2003; 63(16):1697-741.

PMID: 12904089 DOI: 10.2165/00003495-200363160-00006.


Clinical pharmacokinetics of vasodilators. Part II.

Kirsten R, Nelson K, Kirsten D, Heintz B Clin Pharmacokinet. 1998; 35(1):9-36.

PMID: 9673832 DOI: 10.2165/00003088-199835010-00002.


Clinical pharmacokinetics and pharmacodynamics of carvedilol.

Morgan T Clin Pharmacokinet. 1994; 26(5):335-46.

PMID: 7914479 DOI: 10.2165/00003088-199426050-00002.


Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

McTavish D, Sorkin E Drugs. 1993; 45(2):232-58.

PMID: 7681374 DOI: 10.2165/00003495-199345020-00006.


Pharmacokinetic and blood pressure effects of carvedilol in patients with chronic renal failure.

Kramer B, Ress K, Erley C, Risler T Eur J Clin Pharmacol. 1992; 43(1):85-8.

PMID: 1505616 DOI: 10.1007/BF02280760.


References
1.
Schnurr E, Widmann L, Glocke M . Efficacy and safety of carvedilol in the treatment of hypertension. J Cardiovasc Pharmacol. 1987; 10 Suppl 11:S101-7. View

2.
Eggertsen R, SIVERTSSON R, Andren L, Hansson L . Haemodynamic effects of carvedilol, a new beta-adrenoceptor blocker and precapillary vasodilator in essential hypertension. J Hypertens. 1984; 2(5):529-34. DOI: 10.1097/00004872-198410000-00013. View

3.
Ogihara T, Ikeda M, Goto Y, Yoshinaga K, KUMAHARA Y, Iimura O . The effect of low dose carvedilol on circadian variation of blood pressure in patients with essential hypertension. J Cardiovasc Pharmacol. 1987; 10 Suppl 11:S108-12. View

4.
Heber M, Brigden G, Caruana M, Lahiri A, Raftery E . Carvedilol for systemic hypertension. J Cardiovasc Pharmacol. 1987; 10 Suppl 11:S113-8. View

5.
Louis W, McNeil J, Workman B, Drummer O, Conway E . A pharmacokinetic study of carvedilol (BM 14.190) in elderly subjects: preliminary report. J Cardiovasc Pharmacol. 1987; 10 Suppl 11:S89-93. View